Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
Southwestern Medical Center · The University of Texas Southwestern Medical Center · +11 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
8
total citations
- FWCI
- 106.75
- Percentile
- 100%
- References
- 27
Too recent for citation history.
Authors
13- ACAdam C. YoppCorresponding
Southwestern Medical Center, The University of Texas Southwestern Medical Center
- MCM. C. Chen
Sun Yat-sen University, Sun Yat-sen University Cancer Center
- ACAnn-Lii Cheng
National Taiwan University Hospital
- AKAhmed Kaseb
The University of Texas MD Anderson Cancer Center
- MKMasatoshi Kudo
Kindai University
Topics & keywords
Topics
Keywords
- Atezolizumab
- Bevacizumab
- Adjuvant
- Interim analysis
- Hepatocellular carcinoma
- Perioperative
- Adjuvant therapy
- Adjuvant chemotherapy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.